<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0101-5907</journal-id>
<journal-title><![CDATA[Revista Paraense de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Para. Med.]]></abbrev-journal-title>
<issn>0101-5907</issn>
<publisher>
<publisher-name><![CDATA[Fundação Santa Casa de Misericórdia do Pará]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0101-59072006000400005</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Prevalência de IgG do vírus varicela-zoster (VVZ) em indígenas da tribo Araweté, em Altamira, Pará, de janeiro-fevereiro de 2001]]></article-title>
<article-title xml:lang="en"><![CDATA[Prevalence of IgG of the varicela zoster vírus (VZV) in the indigenous tribe Araweté, Altamira, Pará, from january-february 2001]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[Marcos Rogério Menezes da]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[Carlos Sousa]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Monteiro]]></surname>
<given-names><![CDATA[Talita Antonia Furtado]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Biomédico, Mestre em Biologia de Agentes Infecciosos e Parasitários - UFPa  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Biomédico, Universidade Federal do Pará  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A03">
<institution><![CDATA[,Enfermeira Pesquisadora da Seção de Virologia do Instituto Evandro Chagas  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2006</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2006</year>
</pub-date>
<volume>20</volume>
<numero>4</numero>
<fpage>23</fpage>
<lpage>28</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_arttext&amp;pid=S0101-59072006000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_abstract&amp;pid=S0101-59072006000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_pdf&amp;pid=S0101-59072006000400005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Objetivo: determinar a prevalência de anticorpos IgG para o vírus da varicela-zoster (VVZ) em indivíduos da comunidade indígena Araweté, Altamira, Pará, Brasil. Método: foram testadas 357 amostras de soros de indivíduos residentes na comunidade indígena Araweté, coletadas em janeiro e fevereiro de 2001, após um surto grave causado por esse vírus. Utilizou-se o procedimento imunoenzimático (ELISA) "Kit" da "Clark LaboratorieisTM" (Jamestown-NY-EUA) na pesquisa de anticorpos IgG para o VVZ. Resultados: as 357 amostras analisadas mostraram taxa de 83,2% (297/357) de positividade. O sexo feminino foi mais acometido que o masculino, com 88,0% (162/184) e 78,0% (135/173), respectivamente, resultando diferença estatisticamente significativa, p= 0,017. A freqüência de soropositividade até os 20 anos de idade foi de 64,0% (190/297). Conclusão: aproximadamente 17% do total de indivíduos pesquisados, ainda não apresentam imunidade contra o VVZ. Os autores recomendam a necessidade de vacinação de rotina contra varicela na população suscetível, a fim de conferir proteção contra doença severa em comunidades não imunes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Objective: the aim of the study was to determine the prevalence of anti-VZV antibodies of immunoglobulin G class (IgG) among remote indian communities living in the central-west region of Pará state, in the municipality of Altamira. Method: serum samples were collected in January 2000 from the Araweté Indians group after the notification of in outbreak of chickenpox starty with 12 cases. VZV-IgG antibodies were measured by enzyme-linked immunosorbent assay (ELISA), using a commercial kit (Clark LaboratoriesTM, Jamestown-NY-USA). Results: of the 357 tested, 297 (83%) were IgG-positive, of which 45,3% (135/297) were from male indians and 54,7% (162/297) from females individuals. Rates of seropositivity up to 20 years of age was 64,0% (190/297). In addition, frequencies of seropositivity were consistently higher in females than in males (p=0,017). Conclusion: about 17% of the total of searched individuals, still they do not present immunity against the VZV. The need for routine vaccination against varicella of susceptible population is recommended, in order to confer protection against severe disease among these non-immune communities.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[varicela]]></kwd>
<kwd lng="pt"><![CDATA[herpes zoster]]></kwd>
<kwd lng="pt"><![CDATA[índios Araweté]]></kwd>
<kwd lng="en"><![CDATA[varicella]]></kwd>
<kwd lng="en"><![CDATA[Shingles]]></kwd>
<kwd lng="en"><![CDATA[Araweté indians]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font size="2" face="Verdana"><b><a name="topo"></a>ARTIGO ORIGINAL</b></font></p>     <p>&nbsp;</p>     <p><b><font size="4" face="Verdana">Preval&ecirc;ncia de IgG do v&iacute;rus varicela-zoster    (VVZ) em ind&iacute;genas da tribo Arawet&eacute;, em Altamira, Par&aacute;,    de janeiro-fevereiro de 2001<sup><a href="#nota"><font size="3">1</font></a></sup></font></b></p>     <p>&nbsp;</p>     <p><b><font size="3" face="Verdana">Prevalence of IgG of the varicela zoster v&iacute;rus    (VZV) in the indigenous tribe Arawet&eacute;, Altamira, Par&aacute;, from january-february    2001</font></b></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><b>Marcos Rog&eacute;rio Menezes da Costa<sup>I</sup>;    Carlos Sousa Ramos<sup>II</sup>; Talita Antonia Furtado Monteiro<sup>III</sup></b></font></p>     <p><font size="2" face="Verdana"><sup>I</sup>Biom&eacute;dico, Mestre em Biologia    de Agentes Infecciosos e Parasit&aacute;rios - UFPa    <br>   <sup>II</sup>Biom&eacute;dico, Universidade Federal do Par&aacute;    ]]></body>
<body><![CDATA[<br>   <sup>III</sup>Enfermeira Pesquisadora da Se&ccedil;&atilde;o de Virologia do    Instituto Evandro Chagas</font></p>     <p><font size="2" face="Verdana"><a href="#endereco">Endere&ccedil;o para correspond&ecirc;ncia</a></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p> <hr size="1" noshade>     <p><font size="2" face="Verdana"><b>RESUMO</b></font></p>     <p><font size="2" face="Verdana"><b><i>OBJETIVO:</i></b><i> determinar a preval&ecirc;ncia    de anticorpos IgG para o v&iacute;rus da varicela-zoster (VVZ) em indiv&iacute;duos    da comunidade ind&iacute;gena Arawet&eacute;, Altamira, Par&aacute;, Brasil.    <br>   <b>M&Eacute;TODO:</b> foram testadas 357 amostras de soros de indiv&iacute;duos    residentes na comunidade ind&iacute;gena Arawet&eacute;, coletadas em janeiro    e fevereiro de 2001, ap&oacute;s um surto grave causado por esse v&iacute;rus.    Utilizou-se o procedimento imunoenzim&aacute;tico (ELISA) &quot;Kit&quot; da    &quot;Clark LaboratorieisTM&quot; (Jamestown-NY-EUA) na pesquisa de anticorpos    IgG para o VVZ.    <br>   <b>RESULTADOS:</b> as 357 amostras analisadas mostraram taxa de 83,2% (297/357)    de positividade. O sexo feminino foi mais acometido que o masculino, com 88,0%    (162/184) e 78,0% (135/173), respectivamente, resultando diferen&ccedil;a estatisticamente    significativa, p= 0,017. A freq&uuml;&ecirc;ncia de soropositividade at&eacute;    os 20 anos de idade foi de 64,0% (190/297).    <br>   <b>CONCLUS&Atilde;O:</b> aproximadamente 17% do total de indiv&iacute;duos pesquisados,    ainda n&atilde;o apresentam imunidade contra o VVZ. Os autores recomendam a    necessidade de vacina&ccedil;&atilde;o de rotina contra varicela na popula&ccedil;&atilde;o    suscet&iacute;vel, a fim de conferir prote&ccedil;&atilde;o contra doen&ccedil;a    severa em comunidades n&atilde;o imunes.</i></font></p>     <p><font size="2" face="Verdana"><b>Descritores:</b> varicela; herpes zoster;    &iacute;ndios Arawet&eacute;.</font></p> <hr size="1" noshade>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"><b>SUMMARY</b></font></p>     <p><font size="2" face="Verdana"><b>OBJECTIVE:</b> the aim of the study was to    determine the prevalence of anti-VZV antibodies of immunoglobulin G class (IgG)    among remote indian communities living in the central-west region of Par&aacute;    state, in the municipality of Altamira.    <br>   <b>METHOD:</b> serum samples were collected in January 2000 from the Arawet&eacute;    Indians group after the notification of in outbreak of chickenpox starty with    12 cases. VZV-IgG antibodies were measured by enzyme-linked immunosorbent assay    (ELISA), using a commercial kit (Clark LaboratoriesTM, Jamestown-NY-USA).    <br>   <b>RESULTS:</b> of the 357 tested, 297 (83%) were IgG-positive, of which 45,3%    (135/297) were from male indians and 54,7% (162/297) from females individuals.    Rates of seropositivity up to 20 years of age was 64,0% (190/297). In addition,    frequencies of seropositivity were consistently higher in females than in males    (p=0,017).    <br>   <b>CONCLUSION:</b> about 17% of the total of searched individuals, still they    do not present immunity against the VZV. The need for routine vaccination against    varicella of susceptible population is recommended, in order to confer protection    against severe disease among these non-immune communities.</font></p>     <p><font size="2" face="Verdana"><b>Key-words:</b> varicella; Shingles; Arawet&eacute;    indians.</font></p> <hr size="1" noshade>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>INTRODU&Ccedil;&Atilde;O</b></font></p>     <p><font size="2" face="Verdana">A varicela &eacute; uma doen&ccedil;a contagiosa    que possui vacina, e ocorre, principalmente, durante a inf&acirc;ncia, como    uma conseq&uuml;&ecirc;ncia da infec&ccedil;&atilde;o prim&aacute;ria pelo v&iacute;rus    varicela-zoster (VVZ). Apesar de decorrer, geralmente, de forma benigna, pode    causar algumas complica&ccedil;&otilde;es, especialmente em indiv&iacute;duos    de grupo de risco (pacientes com neoplasias e s&iacute;ndrome da imunodefici&ecirc;ncia    adquirida - SIDA). A morbidade e a mortalidade, devido &agrave; varicela, s&atilde;o,    significativamente, elevados em adultos<sup>1</sup>.</font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">O VVZ &eacute; respons&aacute;vel por dois quadros    cl&iacute;nicos: a varicela e o herpes zoster. A patogenia da varicela inicia-se    com a fase de viremia durante o per&iacute;odo de incuba&ccedil;&atilde;o da    doen&ccedil;a, resultante da replica&ccedil;&atilde;o viral nas c&eacute;lulas    epiteliais cut&acirc;neas, produzindo les&otilde;es caracter&iacute;sticas da    varicela. No herpes zoster, o v&iacute;rus evolui de um g&acirc;nglio sensorial    via ax&ocirc;nio neuronal para a epiderme desencadeando a fase conhecida como    dermatoma, que corresponde &agrave; doen&ccedil;a localizada<sup>2</sup>. Apesar    da transmiss&atilde;o ocorrer aparentemente na juventude, a viremia, tamb&eacute;m,    pode acontecer durante a reativa&ccedil;&atilde;o do VVZ, como detectada pela    presen&ccedil;a do &aacute;cido desoxirribonucl&eacute;ico (ADN) viral em c&eacute;lulas    mononucleares perif&eacute;ricas (PBMC) de alguns pacientes com zoster dermatomal    e zoster associada &agrave; dor.<sup>3, 4,5</sup></font></p>     <p><font size="2" face="Verdana">Investiga&ccedil;&otilde;es soroepidemiol&oacute;gicas    em pa&iacute;ses desenvolvidos t&ecirc;m demonstrado que, at&eacute; os 20 anos    de idade, acerca de 90% da popula&ccedil;&atilde;o j&aacute; foi exposta &agrave;    infec&ccedil;&atilde;o e est&atilde;o protegidas.<sup>6</sup></font></p>     <p><font size="2" face="Verdana">Com o crescente n&uacute;mero de crian&ccedil;as    em idade pr&eacute;-escolar freq&uuml;entando creches, a infec&ccedil;&atilde;o    tende a ocorrer em idade mais precoce. Por&eacute;m, estudos conduzidos por    FAIRLEY &amp; MILLER (1996) reportam o aumento de casos sintom&aacute;ticos    em adultos<sup>7</sup>.</font></p>     <p><font size="2" face="Verdana">As principais complica&ccedil;&otilde;es s&atilde;o    as infec&ccedil;&otilde;es bacterianas secund&aacute;rias e pneumonia. Com evolu&ccedil;&atilde;o    de hemorragias, hepatites, artrites e s&iacute;ndrome de Reye, sendo mais severas    em adultos jovens, e com mortalidade 25 vezes mais alta do que em crian&ccedil;as.    <sup>4,5</sup></font></p>     <p><font size="2" face="Verdana">A epidemiologia da doen&ccedil;a est&aacute;    associada a fatores intr&iacute;nsecos do hospedeiro que podem levar &agrave;    reativa&ccedil;&atilde;o do v&iacute;rus latente. A maioria dos casos ocorre    com indiv&iacute;duos de mais de 45 anos. A incid&ecirc;ncia aumenta com a idade,    para mais de 10 casos por 1000 pessoas/ano, aos 75 anos de idade. Herpes zoster,    raramente, ocorre em crian&ccedil;as saud&aacute;veis que receberam vacinas    para varicela. TAKAYAMA <i>et al</i>., 2000 citam que a incid&ecirc;ncia de    zoster na faixa et&aacute;ria infantil tem sido encontrada em torno de 14 casos    por 100.000 pessoas/ano<sup>8</sup>.</font></p>     <p><font size="2" face="Verdana">Investiga&ccedil;&otilde;es conduzidas em comunidades    isoladas, segundo BECKER <i>et al</i>. (1988) citam que 76% das crian&ccedil;as    ind&iacute;genas menores de 15 anos exibiram positividade para o VVZ em Navajo    (EUA).<sup>9</sup></font></p>     <p><font size="2" face="Verdana">No Brasil, BLACK <i>et al</i>., 1970<sup>10</sup>    em estudo pr&eacute;vio referem uma preval&ecirc;ncia em torno de 41%. Ainda    na regi&atilde;o amaz&ocirc;nica BLACK (1975)<sup>11</sup> reporta que as comunidades    isoladas funcionam como uma importante ferramenta na hist&oacute;ria e na reconstru&ccedil;&atilde;o    heredit&aacute;ria das doen&ccedil;as. Mais recentemente, MONTEIRO <i>et al</i>.    (2002) em trabalho envolvendo comunidades ind&iacute;genas, citam percentuais    em torno de 80% para esses agentes virais.<sup>12</sup></font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>OBJETIVO</b></font></p>     <p><font size="2" face="Verdana">Avaliar o perfil imunol&oacute;gico e a preval&ecirc;ncia    de anticorpos IgG do v&iacute;rus varicela-zoster, diante do surto epid&ecirc;mico    ocorrido em indiv&iacute;duos da comunidade ind&iacute;gena Arawet&eacute; em    Altamira, Par&aacute;, Brasil, per&iacute;odo de janeiro a fevereiro de 2001.</font></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>M&Eacute;TODO</b></font></p>     <p><font size="2" face="Verdana"><b>Amostras</b></font></p>     <p><font size="2" face="Verdana">Os Arawet&eacute; s&atilde;o uma popula&ccedil;&atilde;o    tupi-guarani de ca&ccedil;adores e agricultores de floresta de terra firme,    que se deslocou h&aacute; cerca de 35 anos das cabeceiras do rio Bacaj&aacute;,    a sudeste, em dire&ccedil;&atilde;o ao Xingu, no Estado do Par&aacute;.</font></p>     <p><font size="2" face="Verdana">As amostras sorol&oacute;gicas foram coletadas    nos meses de janeiro e fevereiro de 2001, quando foram enviados dois (2) t&eacute;cnicos    do Instituto Evandro Chagas, Servi&ccedil;o de Vigil&acirc;ncia em Sa&uacute;de    e Minist&eacute;rio da Sa&uacute;de com o prop&oacute;sito de dar apoio cl&iacute;nico-laboratorial    ao surto epid&ecirc;mico de VVZ, ocorrido entre os &iacute;ndios Arawet&eacute;.</font></p>     <p><font size="2" face="Verdana">Analisados 357 soros de &iacute;ndios Arawat&eacute;,    pertencentes &agrave;s tribos Apiterewa (9), Arara (56), Bakaja (6), Curu&aacute;    (14), Curuaia (30), Ipixuna (63), Juruna (5), Kaiap&oacute; (20), Karara&ocirc;    (27), Koatinemo (39), Parakana (21), Pat-Kro (7), Tukaman (9), Xingu (38), Xipaia    (13).</font></p>     <p><font size="2" face="Verdana"><b>Procedimento</b></font></p>     <p><font size="2" face="Verdana">Todos os esp&eacute;cimes foram analisados pelo    m&eacute;todo imunoenzim&aacute;tico quanto &agrave; presen&ccedil;a de anticorpos    IgG para VVZ (ELISA), (&quot;Kit&quot; da &quot;Clark LaboratoriesTM&quot;,    Jammestown-NY-EUA). Segundo BAKERMANN (1980), a t&eacute;cnica utilizada apresenta    taxas de sensibilidade e especificidade de 99,4% e 97%, respectivamente (<a href="#fig1">Figura    1</a>).<sup>13</sup></font></p>     <p><a name="fig1"></a></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p align="center"><img src="/img/revistas/rpm/v20n4/4a05f1.gif"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><b>An&aacute;lise estat&iacute;stica</b></font></p>     <p><font size="2" face="Verdana">Os dados foram analisados, essencialmente, com    o recurso de um &quot;software&quot; (Epi-info/ vers&atilde;o 6.0) &#8211; &quot;Centers    for Disease Control and Prevention&quot;, Atlanta, Ge&oacute;rgia, EUA. Os testes    estat&iacute;sticos compreenderam: o qui-quadrado (x<sup>2</sup>), com a corre&ccedil;&atilde;o    de Yates e teste exato de Fisher, quando apropriados.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>RESULTADOS</b></font></p>     <p><font size="2" face="Verdana">Do total de 357 amostras sorol&oacute;gicas de    indiv&iacute;duos da comunidade ind&iacute;gena Arawet&eacute; analisadas, 48,5%    (173/357) eram do sexo masculino e 51,5% (184/357) do feminino. Em 83,2% (297/357)    do total observou-se a presen&ccedil;a de anticorpos da classe IgG para o v&iacute;rus    varicela zoster (<a href="#fig2">figura 2</a>). O sexo feminino foi mais acometido    que </font><font size="2" face="Verdana">o masculino, com 88% (162/184) e 78%    (135/173), respectivamente. Nos grupos et&aacute;rios de &#8804; 10 anos, 11-20,    21-30, 31 a 40 e &gt;40 anos, verificaram-se &iacute;ndices de preval&ecirc;ncia    de 76,1%, 94,5%, 88,6%, 97,1% e 73,9%, respectivamente, para os casos estudados    nesse per&iacute;odo. Os &iacute;ndices de soropositividade nas aldeias variaram    de 35% a 100% (<a href="#tab1">tabela 1</a>).</font></p>     <p><a name="fig2"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/rpm/v20n4/4a05f2.gif"></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><a name="tab1"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/rpm/v20n4/4a05t1.gif"></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>DISCUSS&Atilde;O</b></font></p>     <p><font size="2" face="Verdana">Os achados revelaram o elevado &iacute;ndice    de soropositividade de 83,2% (297/357), se comparados com estudos pr&eacute;vios    conduzidos por BLACK <i>et al</i>., (1970)<sup>10</sup> em que somente 41% (21/51)    dos indiv&iacute;duos da comunidade ind&iacute;gena Tiriy&oacute; possu&iacute;am    anticorpos para esses v&iacute;rus. Os &iacute;ndices encontrados na comunidade    ind&iacute;gena Arawet&eacute; de soropositividade do anti-VVZ em todos os grupos    et&aacute;rios foram elevados, dados estes similares aos de CLEMENS <i>et al</i>.,    (1999),<sup>14 </sup>em estudos realizados em popula&ccedil;&otilde;es urbanas    de algumas capitais brasileiras, como Rio de Janeiro (83,3%), Porto Alegre (83,7%),    e Fortaleza (89%), evidenciando-se uma forte correla&ccedil;&atilde;o com a    idade, principalmente, no grupo de crian&ccedil;as at&eacute; 11 anos.</font></p>     <p><font size="2" face="Verdana">A taxa de soropositividade de anticorpos IgG    para o VVZ encontrada por LAFER <i>et al</i>., 2005,<sup>15</sup> em estudo    realizado em duas aldeias ind&iacute;genas do Parque Nacional do Xingu, grupo    et&aacute;rio at&eacute; 10 anos (66,4%), de 11 at&eacute; 20 anos (98,6%) e    21 ou mais anos (100%), foram semelhantes com os resultados encontrados na comunidade    ind&iacute;gena Arawet&eacute;, grupo et&aacute;rio at&eacute; 10 anos (76%),    de 11 at&eacute; 20 anos (94,5%) e 21 ou mais anos (85,6%). Em S&atilde;o Paulo    a presen&ccedil;a de anticorpos variou entre 50% a 75% (COSTA <i>et al</i>.,1996)<sup>16</sup> dependendo do n&iacute;vel s&oacute;cio-econ&ocirc;mico estudado. Isso sugere    uma ampla circula&ccedil;&atilde;o desse v&iacute;rus tanto em comunidades isoladas    quanto em comunidades urbanas.</font></p>     <p><font size="2" face="Verdana">Observou-se que o sexo feminino foi mais acometido    pelo VVZ, fato que pode ser justificado pelo conv&iacute;vio das mulheres com    os indiv&iacute;duos infectados, geralmente crian&ccedil;as, considerado costume    predominante da tribo; indiv&iacute;duos do sexo masculino permanecem a </font><font size="2" face="Verdana">maior    parte do tempo ausente pelas atividades de ca&ccedil;a e pesca.Vale ressaltar    que nas aldeias Kaiap&oacute; e Koatinemo, os &iacute;ndices de imunidade s&atilde;o    muito baixos, variando de 35,0% a 53,8%. Fato que pode ter possibilitado a ocorr&ecirc;ncia    do surto em dezembro de 2000, com um caso de &oacute;bito, associado &agrave;    VVZ com confirma&ccedil;&atilde;o cl&iacute;nica e laboratorial.</font></p>     <p><font size="2" face="Verdana">BECKER <i>et al</i>., (1988)<sup>9</sup> conduziram    um estudo entre crian&ccedil;as com at&eacute; 15 anos, pertencentes &agrave;    comunidade ind&iacute;gena de Navajo (EUA), e observaram que 76,5% (143/187)    tinham anticorpos para VVZ. &Iacute;ndice similar de 80% (163/204) foi encontrado    em nossas amostras quando comparados com a mesma faixa et&aacute;ria. (dados    n&atilde;o exibidos).</font></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>CONCLUS&Atilde;O</b></font></p>     <p><font size="2" face="Verdana">Esses resultados oferecem subs&iacute;dios para    que estrat&eacute;gias de vacina&ccedil;&atilde;o sejam implementadas na comunidade    ind&iacute;gena pesquisada, onde cerca de 17,0% do total de indiv&iacute;duos    pesquisados, ainda n&atilde;o possuem imunidade para o VVZ. Ali&aacute;s, merece    importante aten&ccedil;&atilde;o a comunidade ind&iacute;gena Kaiap&oacute;,    com 1/3 dos indiv&iacute;duos suscet&iacute;veis &agrave; infec&ccedil;&atilde;o    pelo VVZ, possibilitando a ocorr&ecirc;ncia de novos surtos epid&ecirc;micos.    A vacina&ccedil;&atilde;o configura-se importante para os adultos, pois a infec&ccedil;&atilde;o    nessa faixa et&aacute;ria, geralmente evolui com certa gravidade. Essas comunidades    isoladas ainda t&ecirc;m como agravante o dif&iacute;cil acesso, tornando-se    demorada a assist&ecirc;ncia m&eacute;dica, e possibilitando a ampla dissemina&ccedil;&atilde;o    do VVZ.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>AGRADECIMENTOS</b></font></p>     <p><font size="2" face="Verdana">Os autores agradecem aos t&eacute;cnicos de pesquisa    Francisco Teles Pantale&atilde;o, Antonia dos Santos Alves e Alessandra Polaro    pela valiosa contribui&ccedil;&atilde;o durante as atividades de campo e laboratorial    realizadas na Se&ccedil;&atilde;o de Virologia do Instituto Evandro Chagas,    SVS/MS.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>REFER&Ecirc;NCIAS</b></font></p>     <!-- ref --><p><font size="2" face="Verdana">1. GERSHON, AA; TAKAHASHI, M. &amp; SEWARD, J.    Varicella vaccine. In: Plotkin,SA &amp; Orenstein, WA, Ed. <i>Vaccine</i>. Philadelphia,    Saunders, 2004; 4: 783-823.</font><!-- ref --><p><font size="2" face="Verdana">2. THOMAS, MB; JURG, HC; JAN-OLAF, G. Fatal varicella-zoster    v&iacute;rus, antigen-positive giant cell arteritis of the central nervous system.    <i>The</i> <i>Pediatric Infectous Disease Journal</i>, 2000; 19: 653-6.</font><!-- ref --><p><font size="2" face="Verdana">3. JUNKER, AK; ANGUS, E; THOMAS, EE. Reccurent    Varicella-Zoster V&iacute;rus Infections. In Apparently Immunocompetent Children.    <i>Pediatric Infectous Diseases</i>, 1991; 10: 569.</font><!-- ref --><p><font size="2" face="Verdana">4. CHOO, PW; DONAHUE, JG; MANSON, JE; PLATT,    R. The epidemiology varicella and its complications. <i>The Journal of Infectious    Disease</i>, 1995; 172: 706.</font><!-- ref --><p><font size="2" face="Verdana">5. GUESS, HA; BROUGHTON, DD; MELTON, LJ; KURLAND,    LT. Population studies of varicella complications. <i>Pediatrics</i>, 1986,    78 (S1): 723.</font><!-- ref --><p><font size="2" face="Verdana">6. WELLER, TH. Varicella and Herpes Zoster: A    perspective and overvs. <i>Pediatric Infectous Disease</i>, 1992; 166 (S1).</font><!-- ref --><p><font size="2" face="Verdana">7. FAIRLEY, CK; MILLER, E. Varicella-Zoster Virus    epidemiology. <i>The Journal of Infectous Disease</i>, 1996; 174 (S 3): 314.</font><!-- ref --><p><font size="2" face="Verdana">8. TAKAYAMA, N; TAKAYAMA, M; TAKITA J. Herpes    Zoster in healthy children immunized with varicella vaccine. Pediatric Infectious    Disease Journal, 2000; 2: 169-170.</font><!-- ref --><p><font size="2" face="Verdana">9. BECKER, TM; MAGDER, L; HARRISON, HR; STEWART,    JA, HUMPHREY, DD; HAULER, J; NAHMIAS, AJ. The epidemiology of infection with    the human herpesviruses in Navajo children. <i>American Journal Epidemiology</i>,    1988; 127 (5): 1071-8.</font><!-- ref --><p><font size="2" face="Verdana">10. BLACK, FL; WOODALL, JP; EVANS, AS; LIEBHABER,    H; HENLE, G. Prevalence of antibody against viruses in the Tiriyo, an isolated    Amazon tribe. <i>American Journal Epidemiology</i>, 1970; 91: 430-8.</font><!-- ref --><p><font size="2" face="Verdana">11. BLACK, F L. Infectious diseases in primitive    societies. <i>Science</i>, 1975; 187: 515-518.</font><!-- ref --><p><font size="2" face="Verdana">12. MONTEIRO, TAF; MENEZES, MRC; RAMOS, CS. Prevalence    of antibodies to Varicella Zoster Virus (VZV) among Tupi-Guarani indians, Altamira,    Par&aacute; State. <i>Virus Reviews &amp; Research</i>. XIII National Meeting    of Virology (Resumo), 2002; 7(1): 116.</font><!-- ref --><p><font size="2" face="Verdana">13. BAKERMAN, S. Enzyme Immunoassays. <i>Lab    Mgmt</i>, august 1980: 21-29.</font><!-- ref --><p><font size="2" face="Verdana">14. CLEMENS, SAC; AZEVEDO, T; FONSECA, JC. Soroepidemiologia    da varicela no Brasil - Resultados de um estudo prospectivo transversal. Rio    De Janeiro. <i>Journal of Pediatric</i>, 1999; 75 (6): 443-441.</font><!-- ref --><p><font size="2" face="Verdana">15. LAFER, MM; De MORAES-PINTO, MI &amp; Weckx,    LY. Prevalence of IgG Varicella Zoster Virus antibodies in the Kuikuro and Kaiabi    indigenous communities in Xingu National Park, Brazil, before Varicella Vaccination.    <i>Revista do Instituto de Medicina Tropical de S&atilde;o Paulo</i>, 2005;    47(3): 139-142.</font><!-- ref --><p><font size="2" face="Verdana">16. COSTA, JM; PANNUTTI, CS; SOUZA, VAUF; AZEVEDO-NETO,    RS; SILVEIRA, ASB e SOUZA, LR <i>et al</i>. Seroepidemiology of Varicella Zoster    Virus (VZV) in two cities of Sao Paulo States, Brazil. <i>7th International    Congress For Infectious Diseases</i>, 10 - 13 June, Hong Kong; 1996.</font><p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><b><a name="endereco"></a><a href="#topo"><img src="/img/revistas/rpm/v20n4/seta.gif" border="0"></a>Endere&ccedil;o    para correspond&ecirc;ncia:</b>    <br>   Talita Antonia Furtado Monteiro    <br>   Instituto Evandro Chagas &#8211; Secretaria de Vigil&acirc;ncia em Sa&uacute;de    <br>   BR 316 &#8211; KM 07, S/N Bairro: Levil&acirc;ndia.    ]]></body>
<body><![CDATA[<br>   CEP: 67.030-000 Ananindeua-Par&aacute;.    <br>   Fone: (91) 3214-2017    <br>   E-mail: <a href="mailto:talitamonteiro@iec.pa.gov.br">Talitamonteiro@iec.pa.gov.br</a></font></p>     <p><font size="2" face="Verdana">Recebido em 27.10.2006    <br>   Aprovado em 20.12.2006</font></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><a name="nota"></a><sup><a href="#topo">1</a></sup>Trabalho    realizado no Laborat&oacute;rio de Virologia do Instituto Evandro Chagas (Secretaria    de Vigil&acirc;ncia em Sa&uacute;de - SVS/MS)</font></p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GERSHON]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[TAKAHASHI]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[SEWARD]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Varicella vaccine]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Plotkin]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Orenstein, WA]]></surname>
<given-names><![CDATA[Ed]]></given-names>
</name>
</person-group>
<source><![CDATA[Vaccine]]></source>
<year>2004</year>
<page-range>783-823</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[THOMAS]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[JURG]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[JAN-OLAF]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Fatal varicella-zoster vírus: antigen-positive giant cell arteritis of the central nervous system]]></article-title>
<source><![CDATA[The Pediatric Infectous Disease Journal]]></source>
<year>2000</year>
<volume>19</volume>
<page-range>653-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[JUNKER]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[ANGUS]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[THOMAS]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Reccurent Varicella-Zoster Vírus Infections: Apparently Immunocompetent Children]]></article-title>
<source><![CDATA[Pediatric Infectous Diseases]]></source>
<year>1991</year>
<volume>10</volume>
<page-range>569</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CHOO]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[DONAHUE]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[MANSON]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[PLATT]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The epidemiology varicella and its complications]]></article-title>
<source><![CDATA[The Journal of Infectious Disease]]></source>
<year>1995</year>
<volume>172</volume>
<page-range>706</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GUESS]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[BROUGHTON]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[MELTON]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[KURLAND]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Population studies of varicella complications]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>1986</year>
<volume>78</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>723</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WELLER]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Varicella and Herpes Zoster: A perspective and overvs]]></article-title>
<source><![CDATA[Pediatric Infectous Disease]]></source>
<year>1992</year>
<volume>166</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FAIRLEY]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[MILLER]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Varicella-Zoster Virus epidemiology]]></article-title>
<source><![CDATA[The Journal of Infectous Disease]]></source>
<year>1996</year>
<volume>174</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>314</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[TAKAYAMA]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[TAKAYAMA]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[TAKITA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Herpes Zoster in healthy children immunized with varicella vaccine]]></article-title>
<source><![CDATA[Pediatric Infectious Disease Journal]]></source>
<year>2000</year>
<volume>2</volume>
<page-range>169-170</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BECKER]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[MAGDER]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[HARRISON]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[STEWART]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[HUMPHREY]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[HAULER]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[NAHMIAS]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The epidemiology of infection with the human herpesviruses in Navajo children]]></article-title>
<source><![CDATA[American Journal Epidemiology]]></source>
<year>1988</year>
<volume>127</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1071-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BLACK]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[WOODALL]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[EVANS]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[LIEBHABER]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[HENLE]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of antibody against viruses in the Tiriyo, an isolated Amazon tribe]]></article-title>
<source><![CDATA[American Journal Epidemiology]]></source>
<year>1970</year>
<volume>91</volume>
<page-range>430-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BLACK]]></surname>
<given-names><![CDATA[F L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Infectious diseases in primitive societies]]></article-title>
<source><![CDATA[Science]]></source>
<year>1975</year>
<volume>187</volume>
<page-range>515-518</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MONTEIRO]]></surname>
<given-names><![CDATA[TAF]]></given-names>
</name>
<name>
<surname><![CDATA[MENEZES]]></surname>
<given-names><![CDATA[MRC]]></given-names>
</name>
<name>
<surname><![CDATA[RAMOS]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of antibodies to Varicella Zoster Virus (VZV) among Tupi-Guarani indians, Altamira, Pará State]]></article-title>
<source><![CDATA[Virus Reviews & Research. XIII National Meeting of Virology (Resumo)]]></source>
<year>2002</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>116</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BAKERMAN]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Enzyme Immunoassays]]></article-title>
<source><![CDATA[Lab Mgmt]]></source>
<year>1980</year>
<page-range>21-29</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CLEMENS]]></surname>
<given-names><![CDATA[SAC]]></given-names>
</name>
<name>
<surname><![CDATA[AZEVEDO]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[FONSECA]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Soroepidemiologia da varicela no Brasil: Resultados de um estudo prospectivo transversal. Rio De Janeiro]]></article-title>
<source><![CDATA[Journal of Pediatric]]></source>
<year>1999</year>
<volume>75</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>443-441</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LAFER]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[De MORAES-PINTO]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Weckx]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of IgG Varicella Zoster Virus antibodies in the Kuikuro and Kaiabi indigenous communities in Xingu National Park, Brazil, before Varicella Vaccination]]></article-title>
<source><![CDATA[Revista do Instituto de Medicina Tropical de São Paulo]]></source>
<year>2005</year>
<volume>47</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>139-142</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[COSTA]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[PANNUTTI]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[SOUZA]]></surname>
<given-names><![CDATA[VAUF]]></given-names>
</name>
<name>
<surname><![CDATA[AZEVEDO-NETO]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[SILVEIRA]]></surname>
<given-names><![CDATA[ASB]]></given-names>
</name>
<name>
<surname><![CDATA[SOUZA]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<source><![CDATA[Seroepidemiology of Varicella Zoster Virus (VZV) in two cities of Sao Paulo States, Brazil: 7th International Congress For Infectious Diseases]]></source>
<year>1996</year>
<publisher-loc><![CDATA[Hong Kong ]]></publisher-loc>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
